May 3, 2023

May 3, 2023

May 3, 2023

TiEcon 2023

Model Medicines was proud to be represented at TiEcon 2023, the world's largest conference for tech entrepreneurs designed by Silicon Valley leaders for entrepreneurs, corporate executives, and investors.

TiEcon 2023 Recap

Model Medicines was proud to be represented at TiEcon 2023, the world's largest conference for tech entrepreneurs designed by Silicon Valley leaders for entrepreneurs, corporate executives, and investors.

Model Medicines CEO Daniel Haders moderated a dynamic panel on "Innovation is Not Optional. Are You Ready?" featuring industry leaders from Glassbeam, Elevance Health, Roche and more.

The discussion examined how organizations can build cultures of innovation and deploy enabling technologies like AI to reimagine solutions.

Panelists shared perspectives on:

  • Fostering entrepreneurial mindsets

  • Overcoming risk aversion

  • Leveraging data and machine learning

  • Keeping patients at the center

  • Translating R&D into impact

Model Medicines also met with fellow innovators and respected thought leaders across the tech and investment landscape. Conversations focused on technological breakthroughs across biopharma, opportunities in commercialization, global emerging trends, and the positive societal potential of ethical AI.

Learn More

To learn more about Model Medicines and stay updated on the latest news, visit www.modelmedicines.com/investors.

Details

Date

May 3, 2023

Category

Events

Reading

1 Min

Author

Patrick ONeill

Investor Relations

Related News

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases